ATE218537T1 - Verbindungen mit wachstumshormon freisetzenden eigenschaften - Google Patents

Verbindungen mit wachstumshormon freisetzenden eigenschaften

Info

Publication number
ATE218537T1
ATE218537T1 AT97930368T AT97930368T ATE218537T1 AT E218537 T1 ATE218537 T1 AT E218537T1 AT 97930368 T AT97930368 T AT 97930368T AT 97930368 T AT97930368 T AT 97930368T AT E218537 T1 ATE218537 T1 AT E218537T1
Authority
AT
Austria
Prior art keywords
compounds
growth hormone
hormone releasing
releasing properties
formula
Prior art date
Application number
AT97930368T
Other languages
German (de)
English (en)
Inventor
Bernd Peschke
Michael Ankersen
Thomas Kruse Hansen
Henning Thoegersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE218537T1 publication Critical patent/ATE218537T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT97930368T 1996-07-22 1997-07-17 Verbindungen mit wachstumshormon freisetzenden eigenschaften ATE218537T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK80396 1996-07-22
PCT/DK1997/000314 WO1998003473A1 (en) 1996-07-22 1997-07-17 Compounds with growth hormone releasing properties

Publications (1)

Publication Number Publication Date
ATE218537T1 true ATE218537T1 (de) 2002-06-15

Family

ID=8097747

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97930368T ATE218537T1 (de) 1996-07-22 1997-07-17 Verbindungen mit wachstumshormon freisetzenden eigenschaften
AT01123155T ATE304528T1 (de) 1996-07-22 1997-07-17 Verbindungen mit wachstumshormon-freisetzenden eigenschaften

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01123155T ATE304528T1 (de) 1996-07-22 1997-07-17 Verbindungen mit wachstumshormon-freisetzenden eigenschaften

Country Status (8)

Country Link
US (3) US5922770A (2)
EP (2) EP0923539B1 (2)
JP (1) JP4425992B2 (2)
AT (2) ATE218537T1 (2)
AU (1) AU3434697A (2)
DE (2) DE69734215T2 (2)
WO (1) WO1998003473A1 (2)
ZA (1) ZA976371B (2)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1005484A1 (en) * 1997-06-20 2000-06-07 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6127341A (en) * 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
JP4142253B2 (ja) * 1998-05-11 2008-09-03 ノボ ノルディスク アクティーゼルスカブ 成長ホルモン放出特性を有する化合物
TW450954B (en) * 1998-05-14 2001-08-21 Pharmacia & Amp Upjohn Company Phenylsulfonamide-phenylethylamines useful as dopamine receptors
DK1100824T3 (da) * 1998-06-30 2011-06-20 Helsinn Therapeutics Us Inc Forbindelser med væksthormonfrigivende egenskaber
US6919315B1 (en) 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6358951B1 (en) * 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
JP2002542151A (ja) 1999-02-18 2002-12-10 科研製薬株式会社 成長ホルモン分泌促進物質としての新規なアミド誘導体
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
DE60124080T2 (de) * 2000-03-23 2007-03-01 Elan Pharmaceuticals, Inc., San Francisco Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
US7423177B2 (en) * 2001-03-05 2008-09-09 Transtech Pharma, Inc. Carboxamide derivatives as therapeutic agents
US6613801B2 (en) * 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
DE60140285D1 (de) 2000-05-31 2009-12-10 Pfizer Prod Inc Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
EP1666452A2 (en) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
JP2004502664A (ja) * 2000-06-30 2004-01-29 イーラン　ファーマスーティカルズ、インコーポレイテッド アルツハイマー病処置用化合物
HRP20030696A2 (en) * 2001-02-16 2005-04-30 NPS Allelix Corp. Allelix Neuroscience GlyT-1 INHIBITORS
CN1235583C (zh) * 2001-03-05 2006-01-11 特兰斯泰克制药公司 用作治疗剂的苯并咪唑衍生物
BR0210721A (pt) * 2001-06-27 2004-07-20 Elan Pharm Inc Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição
US20070213407A1 (en) * 2001-06-29 2007-09-13 Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc Compounds to treat Alzheimer's disease
DK1471054T3 (da) * 2002-01-11 2009-11-09 Daiichi Sankyo Co Ltd Aminoalkohol-derivat eller phosphonsyre-derivat og medicinsk sammensætning, der indeholder disse
US7230133B2 (en) 2003-05-01 2007-06-12 Bristol-Myers Squibb Company Malonamides and malonamide derivatives as modulators of chemokine receptor activity
WO2005000295A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
NZ549162A (en) 2004-02-24 2009-12-24 Sankyo Co Amino-pyrrol alcohol compounds
KR20070010151A (ko) * 2004-03-30 2007-01-22 사파이어 세라퓨틱스, 인크. 성장 호르몬 분비촉진제를 이용하여 ｃ-반응성 단백질을감소시키는 방법
US7825138B2 (en) * 2004-06-29 2010-11-02 Helsinn Therapeutics (U.S.), Inc. Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
ES2388501T3 (es) * 2004-08-12 2012-10-16 Helsinn Healthcare S.A. Uso de secretagogos de la hormona de crecimiento para estimular la motilidad del sistema gastrointestinal
JP4935675B2 (ja) 2005-08-25 2012-05-23 宇部興産株式会社 光学活性（Ｓ又はＲ）−α−アミノ酸及び光学活性（Ｒ又はＳ）−α−アミノ酸エステルの製造方法
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法
CA2677813A1 (en) * 2007-02-13 2008-08-21 Helsinn Therapeutics (U.S.), Inc. Method of treating cell proliferative disorders using growth hormone secretagogues
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
UA105657C2 (uk) * 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
JP5805646B2 (ja) 2009-09-30 2015-11-04 ブイティーブイ・セラピューティクス・エルエルシー アルツハイマー病の治療のための置換イミダゾール誘導体
ES2711526T3 (es) 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
US9717710B2 (en) 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
WO2017139317A1 (en) 2016-02-09 2017-08-17 Lumeova, Inc Ultra-wideband, wireless optical high speed communication devices and systems
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2020076668A1 (en) 2018-10-10 2020-04-16 Vtv Therapeutics Llc Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017423A1 (en) * 1993-12-23 1995-06-29 Novo Nordisk A/S Compounds with growth hormone releasing properties
ID18218A (id) * 1995-01-27 1998-03-19 Novo Nordisk As Senyawa dengan sifat-sifat pelepas hormon pertumbuhan
CZ195098A3 (cs) * 1995-12-22 1998-10-14 Novo Nordisk A/S Sloučeniny uvolňující růstový hormon

Also Published As

Publication number Publication date
DE69713109D1 (de) 2002-07-11
US5922770A (en) 1999-07-13
DE69734215T2 (de) 2006-06-29
EP0923539A1 (en) 1999-06-23
EP1184370A2 (en) 2002-03-06
EP1184370B1 (en) 2005-09-14
ZA976371B (en) 1998-01-22
US6127354A (en) 2000-10-03
DE69734215D1 (de) 2005-10-20
WO1998003473A1 (en) 1998-01-29
ATE304528T1 (de) 2005-09-15
JP4425992B2 (ja) 2010-03-03
DE69713109T2 (de) 2003-01-02
US6274584B1 (en) 2001-08-14
EP0923539B1 (en) 2002-06-05
AU3434697A (en) 1998-02-10
JP2000515517A (ja) 2000-11-21
EP1184370A3 (en) 2002-03-27

Similar Documents

Publication Publication Date Title
ATE218537T1 (de) Verbindungen mit wachstumshormon freisetzenden eigenschaften
MY113488A (en) Compounds with growth hormone releasing properties
RU94016393A (ru) Пептиды, обладающие способностью к стимулированию высвобождения гормона роста, способ получения, фармацевтическая композиция, способ лечения
ATE69376T1 (de) Haarwuchsmittel.
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DE69333607D1 (de) Vorrichtung zur Herstellung von vorgefüllten, sterilen Abgabevorrichtungen
ATE271874T1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
SG158731A1 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
SE9401406L (sv) Farmaceutiska produkter för att bota tumörsjukdomar samt förfarande för framställning av desamma
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
IT8619055A0 (it) Composizioni farmaceutiche comprendenti peptidi del gruppo colecistochinina-cerulina per il trattamento terapeutico degli statidi shock e dell'insufficienza respiratoria e cardiocircolatoria.
DK0562705T3 (da) Anvendelse af L-deprenyl til fremstilling af et lægemiddel til behandling af Cushings sygdom
DE69716223D1 (de) Vorrichtung zur Herstellung von medizinischen Pflastern zur perkutanen Verabreichung
DE69929616D1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
GR3019774T3 (en) Piperidylmethyl substituted chroman derivatives as agents for the treatment of diseases of the central nervous system
DK0559145T3 (da) Lægemiddel til truende abort
DE69007065D1 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
DE69943239D1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
CO4930262A1 (es) Producto farmaceutico cristalino, su preparacion y uso como sustancia terapeutica
NO970185D0 (no) Anvendelse av (S)-adenosyl-L-metionin (SAMe) og dets fysiologisk kompatible salter for behandling av reperfusjonsskade utlöst av temporær-fokal-ischemi
AP1629A (en) Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes.
RU2001113054A (ru) Способ лечения послеродового острого гнойно-катарального эндометрита коров
WO2001068693A8 (fr) Nouveau polypeptide, proteine humaine de reception cannabinoide 7, et polynucleotide codant pour ce polypeptide
RU2001123759A (ru) Способ лечения одонтогенного остеомиелита, осложненного флегмоной
IT8703464A0 (it) Dispositivo per l'annaffiamento automatico,periodico e controllato di colture

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties